Symbols

VALN

Valneva·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 3

Ample Liquidity

Significant Net Income Decline

RSI Oversold

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VALN

Valneva Se

An innovative biotech company that develops prophylactic vaccines for deadly and infectious diseases

Industry

Biological Technology

Established Date

03/24/1999

Listing Date

05/06/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

674

Fiscal Year Ends

12-31

Website

www.valneva.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Ilot Saint-Joseph Bureaux Convergence Bat. A 12 ter Quai Perrache 69002 Lyon France

Business

Introduction

Valneva SE was incorporated in France on March 24, 1999. The company is a specialty vaccine company focused on the development, manufacture and commercialization of preventive vaccines for infectious diseases. The company takes a highly specialized and targeted approach to vaccine research and development, focusing on vaccine solutions that address unmet needs to ensure that people's lives are transformed. The company uses a deep understanding of vaccine science, including expertise in multiple vaccine models, and established vaccine development capabilities to develop vaccines for diseases that are not yet preventable by vaccines or have limited effective treatment options. The company's current clinical portfolio consists of a number of highly differentiated vaccine candidates designed to provide preventive solutions for diseases with high unmet needs. VLA 1553 targets chikungunya virus and is the first and currently the only chikungunya virus vaccine candidate to publish positive top-line data from a phase III clinical trial, and the first vaccine candidate to submit a Biologics Licensing Application (BLA) to the U.S. Food and Drug Administration (FDA).

Company Financials

EPS

VALN has released its 2024 Q2 earnings. EPS was reported at -0.4, versus the expected -0.34, missing expectations. The chart below visualizes how VALN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VALN has released its 2025 Q4 earnings report, with revenue of 55.97M, reflecting a YoY change of 2.13%, and net profit of -58.70M, showing a YoY change of -53.33%. The Sankey diagram below clearly presents VALN's revenue sources and cost distribution.